Adalimumab ELISA Kit

Used for the quantitative determination of Adalimumab concentration in serum, plasma and cell culture supernatant.

Blue-ice bags

PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant human TNFa antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Adalimumab and then pipetted into the wells. Adalimumab in the sample competitively binds to the pre-coated protein with biotin-labeled Adalimumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Adalimumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Plasma, Serum

Quantitative

Adalimumab is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha (TNF-a) and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.